High levels of TRAIL-R3 and CCR-2 expression in TEpCs identified early breast cancer patients with poor outcomes, including a higher risk of metastasis and shorter DFS, MFS, and OS and represent new independent prognostic factors that may also be suitable therapeutic targets. The gene discussed is CCR2; the disease is breast cancer.